Literature DB >> 21369959

Dose standardisation of anticancer drugs.

Anne-Lise Pouliquen1, Laurence Escalup, Nathalie Jourdan, Paul Cottu, Pierre Faure, Isabelle Madelaine-Chambrin.   

Abstract

OBJECTIVE OF THE STUDY: Body size based dosing is often used for prescribing anticancer drugs. However the scientific and the clinical rationales of this historical method have recently been criticized. As a result, alternative dosing strategies have been suggested, as flat-fixed dosing regimens, but not implemented in routine practice. Dose standardisation is a first step in order to rationalise chemotherapy dose calculation. A new method, derived from dose-banding, was developed, taking into account prescription and economic criteria.
SETTING: Feasibility and interest of this concept were studied in two French cancer centres Institut Curie and Hôpital Saint-Louis. MAIN OUTCOME MEASURES: The aim of our study was to assess dose standardisation of expensive anticancer drugs in objectives of quality and economy.
METHOD: Nine candidate drugs were selected and standardized rounded doses (SRD) were proposed. To determine the specific standard doses of these two centres, two theoretical and practical methods were applied, and then, their results were compared. For each anticancer drug the objective was to fix SRD in order to cover all the doses most frequently prescribed.
RESULTS: It has been possible to propose SRD for six of the nine drugs. These SRD have been implemented with the agreement of the medical staff. These doses are, whenever possible, rounded to the nearest vial size, or correspond to a combination of the different strength of the commercial drug.
CONCLUSION: Our study shows that dose standardisation is a help to optimise the productivity and improve the organisation of the preparation unit.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21369959     DOI: 10.1007/s11096-010-9478-6

Source DB:  PubMed          Journal:  Int J Clin Pharm


  24 in total

1.  Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy.

Authors:  R J Plumridge; G J Sewell
Journal:  Am J Health Syst Pharm       Date:  2001-09-15       Impact factor: 2.637

2.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

3.  'Flat-fixed dosing' of chemotherapy: a concept whose time has come?

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

4.  [Use of body weight and body surface area in dosing of anticancer agents in adult patients].

Authors:  Dominique Levêque
Journal:  Bull Cancer       Date:  2007-07       Impact factor: 1.276

5.  Simplification of drug dosage calculation by application of the surface area principle.

Authors:  J D CRAWFORD; M E TERRY; G M ROURKE
Journal:  Pediatrics       Date:  1950-05       Impact factor: 7.124

6.  Is dose normalization to weight or body surface area useful in adults?

Authors:  L B Grochow; C Baraldi; D Noe
Journal:  J Natl Cancer Inst       Date:  1990-02-21       Impact factor: 13.506

7.  Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Authors:  Sharyn D Baker; Jaap Verweij; Eric K Rowinsky; Ross C Donehower; Jan H M Schellens; Louise B Grochow; Alex Sparreboom
Journal:  J Natl Cancer Inst       Date:  2002-12-18       Impact factor: 13.506

Review 8.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.

Authors:  H Gurney
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

9.  Implications of dose rounding of chemotherapy to the nearest vial size.

Authors:  Michael Joseph Dooley; Sanjay Singh; Michael Michael
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

10.  Getting the right dose in cancer chemotherapy--time to stop using surface area?

Authors:  D R Newell
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

View more
  8 in total

1.  Exploratory analysis for the implementation of antineoplastic logarithmic dose banding.

Authors:  A Albert-Marí; S Valero-García; V Fornés-Ferrer; J L Poveda-Andrés
Journal:  Int J Clin Pharm       Date:  2018-08-10

2.  Dose-Banding of Intravenous Piperacillin-Tazobactam in Pediatric Surgical Inpatients.

Authors:  Indrajit S Karande; Zoy Goff; Jacqueline Kewley; Shailender Mehta; Thomas Snelling
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Sep-Oct

3.  The impact of logarithmic dose banding of anticancer drugs on pharmacy compounding efficiency at Ghent University Hospital.

Authors:  Barbara Claus; Kaat De Pourcq; Nele Clottens; Vibeke Kruse; Paul Gemmel; Johan Vandenbroucke
Journal:  Eur J Hosp Pharm       Date:  2017-03-04

Review 4.  Fixed Dosing of Monoclonal Antibodies in Oncology.

Authors:  Jeroen J M A Hendrikx; John B A G Haanen; Emile E Voest; Jan H M Schellens; Alwin D R Huitema; Jos H Beijnen
Journal:  Oncologist       Date:  2017-07-28

5.  Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.

Authors:  Femke M de Man; G D Marijn Veerman; Esther Oomen-de Hoop; Maarten J Deenen; Didier Meulendijks; Caroline M P W Mandigers; Marcel Soesan; Jan H M Schellens; Esther van Meerten; Teun van Gelder; Ron H J Mathijssen
Journal:  Ther Adv Med Oncol       Date:  2019-04-15       Impact factor: 8.168

6.  Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.

Authors:  E Chatelut; M L White-Koning; R Hj Mathijssen; F Puisset; S D Baker; A Sparreboom
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640

7.  Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.

Authors:  Melanie White-Koning; Caroline Osborne; Angelo Paci; Alan V Boddy; Etienne Chatelut; Gareth J Veal
Journal:  Eur J Cancer       Date:  2018-01-12       Impact factor: 9.162

8.  Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-21       Impact factor: 2.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.